NDTVCenter·
Zydus Life Rises 2% As Bernstein Sees Clearer Path For ALS Drug
Bernstein maintains Outperform on Zydus Life after Novartis exits its ALS drug, improving the commercial landscape for Usnoflast ahead of key clinical data.
Read at NDTV →
Business · 1 sources covering this
Zydus Life Rises 2% As Bernstein Sees Clearer Path For ALS Drug
Bernstein maintains Outperform on Zydus Life after Novartis exits its ALS drug, improving the commercial landscape for Usnoflast ahead of key clinical data.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/6446b5e12b92f1b3216b23c64fb7abead21de963" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Zydus Life Rises 2% As Bernstein Sees Clearer Path For ALS Drug"></iframe>
